Merck & Co., Inc. (MRK)
Merck & Co., Inc. (MRK) from its SEC filings: 2025 revenue $65.0 billion (+1% vs the year before), net margin 28%, free cash flow $12.4 billion. Insider trades, recent filings and a price chart. Free.
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $65.0 billion |
| Revenue growth | +1% |
| Net income | $18.3 billion |
| Net margin | 28.1% |
| Free cash flow | $12.4 billion |
| Diluted EPS | $7.28 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +5% |
| Cash | $6.8 billion |
| Long-term debt | $51.1 billion |
| Share count, 1 year | -1% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.